Pharma Focus Asia

Synplogen and Ginkgo Bioworks Announce Collaborative Efforts to Boost Worldwide DNA Manufacturing and Gene Therapy Platform Services in Japan

Thursday, December 07, 2023

Synplogen Co., a synthetic biology startup emerging from Kobe University's Graduate School of Science, Technology, and Innovation, is set to collaborate with Ginkgo Bioworks (NYSE: DNA), a company at the forefront of developing a platform for cell programming and biosecurity. The two entities have formally entered into a non-binding Memorandum of Understanding ("MOU") with the shared objective of accelerating the global advancement of DNA manufacturing and gene therapy platform services within Japan.

The collaborative efforts between Ginkgo and Synplogen will involve exploring potential global business partnerships in the field of DNA manufacturing. Synplogen's OGAB™ DNA synthesis services, known for their ability to synthesize DNA of various lengths, up to 100 kbp, and handle complex DNA synthesis, including high/low guanine-cytosine content and repeat sequences, will play a significant role in this venture.

Moreover, the partnership aims to extend the accessibility of Ginkgo's gene therapy services in the Japanese market. Synplogen intends to support this expansion by providing business development and marketing assistance, fostering connections between Ginkgo's services and Japanese biotechnology and pharmaceutical companies. Ginkgo, equipped with its end-to-end AAV gene therapy development platform and unique expertise in high-throughput design and synthesis optimization, seeks to drive progress in the Japanese bioeconomy.

Jason Kelly, co-founder and CEO of Ginkgo Bioworks, expressed excitement about the collaboration, highlighting Japan's historical leadership in bioeconomy innovations. He emphasized the partnership with Synplogen as a means to grow their cell and gene therapy service offerings in Japan while contributing to the dynamic and inventive Japanese bioeconomy.

Kazuhiko Yamamoto, Representative Director and CEO of Synplogen, conveyed his appreciation for the recognition of their DNA synthesis technology by Ginkgo Bioworks, a global leader in biofoundry. He looks forward to the positive impact of Ginkgo's contributions in driving growth within Japan's bioeconomy, aligning seamlessly with Synplogen's commitment to advancing innovative solutions in the Japanese biotech sector.

 

Source: prnewswire.com

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024